Morgan Stanley Expects A Verdict On Amgen Vs. Sandoz Enbrel IP Litigation In 1Q19; Firm Estimates 'ABBV could be down 6–8% if the ruling is against Amgen, up 1–2% if it's for Amgen, and ~0% if there is a settlement'